{
    "clinical_study": {
        "@rank": "139563", 
        "arm_group": {
            "arm_group_label": "Oral rigosertib", 
            "arm_group_type": "Experimental", 
            "description": "Patients will be treated with 560 mg oral rigosertib BID (2 times a day) taken on days 1 to 14 of 21-day cycles."
        }, 
        "brief_summary": {
            "textblock": "The study will enroll low risk MDS patients who need red blood cell transfusions and who are\n      refractory to or are not using erythropoiesis-stimulating agents. The purpose of the study\n      is to determine whether oral rigosertib treatment   results in hematological improvements\n      according to the 2006 International Working Group criteria in these patients. The study will\n      also record any side effects that may occur during the study."
        }, 
        "brief_title": "Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Myelodysplastic Syndromes", 
        "condition_browse": {
            "mesh_term": [
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "This will be a Phase II, single-arm, multicenter study (approximately 15 centers). Up to 40\n      transfusion-dependent patients with Low- or Int-1 risk MDS by IPSS will be enrolled and\n      treated with 560 mg oral rigosertib BID taken intermittently (2 weeks on/1 week off\n      regimen). Cycles will be 3 weeks in length.\n\n      Enrollment will proceed as follows:\n\n      In the first cohort, 6 patients will be enrolled initially. If no more than 1 drug-related\n      Grade 3 toxicity (based on NCI CTCAE) is observed during the first 21-day cycle in the first\n      6 enrolled patients, 4 additional patients will be enrolled to complete the first cohort. Up\n      to 3 more successive cohorts of 10 patients each will be enrolled, provided there are at\n      least 1 response in the first cohort (10 patients), 4 responses total in the first and\n      second cohorts (20 patients), and 6 responses total in the first, second and third cohorts\n      (30 patients).\n\n      The study will be stopped if any one of these responses is not met."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of MDS according to World Health Organization (WHO) criteria (Appendix 2)\n             or French-American-British (FAB) classification that must be confirmed by bone marrow\n             (BM) aspirate and/or biopsy within 6 weeks prior to Screening.\n\n          -  Myelodysplastic syndrome (MDS) classified as Low risk or Int-1 risk, according to\n             International Prognostic Scoring System (IPSS) classification; in addition, patients\n             should never have been classified as Int-2 or High-risk since their MDS was\n             diagnosed;\n\n          -  Transfusion dependency defined by transfusion of at least 4 units of Red blood cells\n             (RBC) within 56 days before Screening (pre-transfusion Hgb values values must be \u2264 9\n             g/dL to be taken into account).\n\n          -  Refractory to 8- to 12-week course of Erythropoiesis-stimulating agent (ESA)\n             administered within the past 2 years before enrollment, or erythropoietin (EPO) level\n             \u02c3 500 mU/mL and off ESA for at least 8 weeks before Screening.\n\n          -  Off all other treatments for MDS (azacitidine, decitabine, lenalidomide, ESA,\n             chemotherapy, immunotherapy) for at least 2 weeks prior to Screening.\n\n          -  Eastern Cooperative Oncology Group(ECOG) performance status of 0, 1 or 2.\n\n          -  Willing to adhere to the prohibitions and restrictions specified in this protocol.\n\n          -  The patient must signed an informed consent form (ICF) indicating that s/he\n             understands the purpose of, and procedures required for, the study and is willing to\n             participate.\n\n        Exclusion Criteria:\n\n          -  Ongoing clinically significant anemia due to factors such as iron, vitamin B12, or\n             folate deficiencies, auto-immune or hereditary hemolysis, or gastrointestinal (GI)\n             bleeding.\n\n          -  Serum ferritin < 50 ng/mL.\n\n          -  Hypoplastic MDS (cellularity <10%)\n\n          -  Any active malignancy within the past year, except basal cell or squamous cell skin\n             cancer or carcinoma in situ of the cervix or breast.\n\n          -  Uncontrolled intercurrent illness including, but not limited to, symptomatic\n             congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.\n\n          -  Active infection not adequately responding to appropriate therapy.\n\n          -  Total bilirubin \u2265 2.0 mg/dL not related to hemolysis or Gilbert's disease.\n\n          -  Alanine transaminase (ALT) or aspartate transaminase (AST) \u2265 2.5 x the upper limit of\n             normal (ULN).\n\n          -  Serum creatinine \u2265 2.0 mg/dL.\n\n          -  Ascites requiring active medical management including paracentesis.\n\n          -  Hyponatremia (defined as serum sodium value of < 130 mEq/L).\n\n          -  Female patients who are pregnant or lactating.\n\n          -  Patients who are unwilling to follow strict contraception requirements.\n\n          -  Female patients with reproductive potential who do not have a negative urine\n             pregnancy test at Screening.\n\n          -  Major surgery without full recovery or major surgery within 3 weeks of Screening.\n\n          -  Uncontrolled hypertension (defined as a systolic pressure \u2265 160 mmHg and/or a\n             diastolic pressure \u2265 110 mmHg).\n\n          -  New onset seizures (within 3 months prior to the first dose of rigosertib) or poorly\n             controlled seizures.\n\n          -  Any other concurrent investigational agent or chemotherapy, radiotherapy, or\n             immunotherapy.\n\n          -  Chronic use (\u02c3 2 weeks) of corticosteroids (\u02c3 10 mg/24 hr equivalent prednisone)\n             within 4 weeks of Screening.\n\n          -  Investigational therapy within 4 weeks of Screening.\n\n          -  Psychiatric illness or social situation that would limit the patient's ability to\n             tolerate and/or comply with study requirements."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01904682", 
            "org_study_id": "Onconova 09-07", 
            "secondary_id": "2013-000672-15"
        }, 
        "intervention": {
            "arm_group_label": "Oral rigosertib", 
            "description": "Dose of 560 mg consists of two (2) 280 mg soft gel capsules of rigosertib.", 
            "intervention_name": "Oral rigosertib", 
            "intervention_type": "Drug", 
            "other_name": [
                "ON 01910.Na", 
                "rigosertib sodium"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Hematinics"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Erythrocyte transfusion", 
            "Erythropoiesis-stimulating agent", 
            "International Prognostic Scoring System"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "80045"
                    }, 
                    "name": "Anschutz Cancer Pavilion University of Colorado"
                }, 
                "investigator": {
                    "last_name": "Daniel Pollyea, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford University School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Peter L. Greenberg, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20010"
                    }, 
                    "name": "Washington Cancer Institute at Medstar Washington Hospital Center"
                }, 
                "investigator": {
                    "last_name": "Aarthi Shenoy, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "The University of Chicago"
                }, 
                "investigator": {
                    "last_name": "Lucy A. Godley, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }, 
                    "name": "Greenbaum Cancer Center University of Maryland"
                }, 
                "investigator": {
                    "last_name": "Vu Duong, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "investigator": {
                    "last_name": "Aref Al-Kali, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Brunswick", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08903"
                    }, 
                    "name": "Rutgers Cancer Institute of New Jersey"
                }, 
                "investigator": {
                    "last_name": "Dale Schaar, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10029"
                    }, 
                    "name": "Mount Sinai Medical Center"
                }, 
                "investigator": {
                    "last_name": "Lewis R. Silverman, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Cleveland Clinic Foundation"
                }, 
                "investigator": {
                    "last_name": "Mikkael Sekeres, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "The University of Texas MD Anderson Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Elias Jabbour, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "state": "IDF", 
                        "zip": "75475"
                    }, 
                    "name": "H\u00f4pital Saint-Louis, Service d'H\u00e9matologie"
                }, 
                "investigator": {
                    "last_name": "Pierre Fenaux, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "D\u00fcsseldorf", 
                        "country": "Germany", 
                        "state": "NRW", 
                        "zip": "40225"
                    }, 
                    "name": "Heinrich Heine Universit\u00e4t"
                }, 
                "investigator": {
                    "last_name": "Judith Neukirchen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "K\u00f6ln", 
                        "country": "Germany", 
                        "state": "NRW", 
                        "zip": "50937"
                    }, 
                    "name": "Universit\u00e4tsklinikum K\u00f6ln"
                }, 
                "investigator": {
                    "last_name": "Karl-Anton Kreuzer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "state": "Saxony", 
                        "zip": "01307"
                    }, 
                    "name": "Universit\u00e4tsklinikum Carl Gustav Carus an der Technischen Universit\u00e4t Dresden"
                }, 
                "investigator": {
                    "last_name": "Uwe Platzbecker, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "France", 
                "Germany"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Intermediate-1, Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System", 
        "overall_contact": {
            "email": "fwilhelm@onconova.us", 
            "last_name": "Fran\u00e7ois Wilhelm, MD, PhD", 
            "phone": "(609) 281-7086"
        }, 
        "overall_official": {
            "affiliation": "Onconova Therapeutics, Inc.", 
            "last_name": "Fran\u00e7ois Wilhelm, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The number of patients who achieve hematologic improvement will be documented. Hematologic improvement is defined by the 2006 International Working Group (IWG) response criteria for the erythroid, platelet and neutrophil lineages.", 
            "measure": "Hematologic Improvement", 
            "safety_issue": "No", 
            "time_frame": "24 Weeks"
        }, 
        "reference": {
            "PMID": "21924492", 
            "citation": "Seetharam M, Fan AC, Tran M, Xu L, Renschler JP, Felsher DW, Sridhar K, Wilhelm F, Greenberg PL. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leuk Res. 2012 Jan;36(1):98-103. doi: 10.1016/j.leukres.2011.08.022. Epub 2011 Sep 14."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01904682"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The number of patients with a complete remission or a partial remission will be documented.  Complete remission and partial remission are defined according to 2006 IWG response criteria for MDS. Overall response = complete remission + partial remission.", 
                "measure": "Overall Response", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "The number of weeks a complete remission or a partial remission is observed in a patient will be documented.", 
                "measure": "Duration of Response", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Specific safety parameters and procedures will include recording of medical history, medication history, physical examination, measurement of vital signs (blood pressure, temperature, respiration rate, and pulse), weight, laboratory evaluations, and toxicity and AE assessments.", 
                "measure": "Number of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "source": "Onconova Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Onconova Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}